about
Use of pharmacogenomics in pediatric renal transplant recipients.Neonatal Safety Information Reported to the FDA During Drug Development StudiesDesign of pediatric oral formulations with a low proportion of methadone or phenobarbital for the treatment of neonatal abstinence syndrome.Risk assessment of supply chain for pharmaceutical excipients with AHP-fuzzy comprehensive evaluation.Quantification of theophylline or paracetamol in milk matrices by high-performance liquid chromatography.Production and characterization of spray-dried theophylline powders prepared from fresh milk for potential use in paediatrics
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Pediatric drug development: formulation considerations.
@en
type
label
Pediatric drug development: formulation considerations.
@en
prefLabel
Pediatric drug development: formulation considerations.
@en
P2093
P2860
P1476
Pediatric drug development: formulation considerations.
@en
P2093
Areeg Anwer Ali
Daud Baraka Abdallah
Naseem Ahmad Charoo
P2860
P304
P356
10.3109/03639045.2013.850713
P407
P577
2014-01-31T00:00:00Z